通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫
Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
间充质干细胞——肿瘤免疫治疗的秘密特工：前景、挑战与意外转折
英文原题：Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.
查看英文原题
Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
间充质干细胞（MSC）具有免疫调节能力、肿瘤归巢能力，并可作为治疗药物的递送载体。本综述探讨过继转移MSC在肿瘤进展中的作用、其与肿瘤微环境的相互作用，以及其用于递送抗癌药物、溶瘤病毒和遗传物质的情况。综述还讨论MSC疗法的挑战和局限，例如MSC制剂间的差异以及潜在致瘤效应，并强调需要通过先进基因工程和个体化策略提高治疗效力。文章最后对MSC疗法的未来作出积极展望，指出其有望推动有效且个体化癌症治疗的发展。
展开英文摘要原文
Mesenchymal stem cells (MSCs) are recognized for their immunomodulatory capabilities, tumor-homing abilities, and capacity to serve as carriers for therapeutic agents. This review delves into the role of adoptively transferred MSCs in tumor progression, their interactions with the tumor microenvironment, and their use in delivering anti-cancer drugs, oncolytic viruses, and genetic material.
It also addresses the challenges and limitations associated with MSC therapy, such as variability in MSC preparations and potential tumorigenic effects emphasizing the need for advanced genetic engineering and personalized approaches to enhance therapeutic efficacy. The review concludes with an optimistic outlook on the future of MSC-based therapies, underscoring their promise to develop effective and personalized cancer treatments.
论文信息
- 作者
- Minev T、Balbuena S、Gill JM、Marincola FM、Kesari S、Lin F
- 单位
- CureScience Institute, San Diego, CA 92121, USA.United States
- 文献类型
- 综述
- 期刊
- Oncotarget2024 Nov 22
- 原文标识
- PubMed 39576660 · DOI 10.18632/oncotarget.28672
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →